1. 91 IRON CHELATION AND VITAMIN-D3 IN COMBINATION WITH AZACITIDINE IMPROVES TREATMENT RESPONSE IN 19 HIGH RISK MYELODYSPLASTIC SYNDROMES AFTER AZACITIDINE FAILURE. (April 2015) Authors: Brechemier, D.; Comont, T.; Bertoli, S.; Dutertre, M.; Recher, C.; Adoue, D.; Beyne-Rauzy, O. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 92 IMPACT OF COMORBIDITIES AND GERIATRIC ASSESSMENT IN HIGH RISK MYELODYSPLASTIC SYNDROMES OVER 75 YEARS TREATED WITH AZACITIDINE. Issue 1 (April 2015) Authors: Brechemier, D.; Comont, T.; Bertoli, S.; Lozano, S.; Gerard, S.; Adoue, D.; Lauwers-Cances, V.; Beyne-Rauzy, O. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 94 IMPACT OF COMORBIDITIES ON OVERALL SURVIVAL IN THE ELDERLY WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA TREATED BY AZACITIDINE. Issue 1 (April 2015) Authors: Brechemier, D.; Bertoli, S.; Comont, T.; Balardy, L.; Recher, C.; Lauwers-Cances, V.; Beyne-Rauzy, O. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗